DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

South Korea flag South Korea · Delayed Price · Currency is KRW
17,800
+200 (1.14%)
Aug 14, 2025, 2:40 PM KST
1.14%
Market Cap781.30B
Revenue (ttm)839.08B
Net Income (ttm)57.60B
Shares Out44.39M
EPS (ttm)1,296.85
PE Ratio13.57
Forward PE10.56
Dividend200.00 (1.14%)
Ex-Dividend DateDec 27, 2024
Volume128,676
Average Volume180,899
Open17,770
Previous Close17,600
Day's Range17,600 - 18,030
52-Week Range14,400 - 19,150
Beta0.31
RSI45.26
Earnings DateAug 14, 2025

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sell pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other processed products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-4... [Read more]

Sector Healthcare
Founded 1968
Employees 1,183
Stock Exchange KOSDAQ
Ticker Symbol 086450
Full Company Profile

Financial Performance

In 2024, DongKook Pharmaceutical's revenue was 812.17 billion, an increase of 11.10% compared to the previous year's 730.99 billion. Earnings were 60.77 billion, an increase of 29.92%.

Financial Statements

News

There is no news available yet.